{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:48:58Z","timestamp":1794008938783,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.toxicon.2023.107208","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T20:39:55Z","timestamp":1687898395000},"page":"107208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Botulinum toxin A and neuropathic pain: An update"],"prefix":"10.1016","volume":"232","author":[{"given":"A.","family":"Spagna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Attal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.toxicon.2023.107208_bib49","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","article-title":"Review of a Proposed Mechanism for the Antinociceptive Action of Botulinum Toxin Type A","volume":"26","author":"Aoki","year":"2005","journal-title":"NeuroToxicology"},{"key":"10.1016\/j.toxicon.2023.107208_bib1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/AJP.0b013e31827a72d2","article-title":"Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial","volume":"29","author":"Apalla","year":"2013","journal-title":"Clin. J. Pain"},{"issue":"Suppl. 1","key":"10.1016\/j.toxicon.2023.107208_bib2","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/j.pain.0000000000001522","article-title":"Translational neuropathic pain research","volume":"160","author":"Attal","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.toxicon.2023.107208_bib3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S1474-4422(18)30071-1","article-title":"Diagnosis and assessment of neuropathic pain through questionnaires","volume":"17","author":"Attal","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.toxicon.2023.107208_bib4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1474-4422(16)00017-X","article-title":"Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial","volume":"15","author":"Attal","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.toxicon.2023.107208_bib5","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.pain.2011.09.014","article-title":"The specific disease burden of neuropathic pain: results of a French nationwide survey","volume":"152","author":"Attal","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.toxicon.2023.107208_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2010.01.020","article-title":"Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection","volume":"633","author":"Bach-Rojecky","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.toxicon.2023.107208_bib7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/ene.13950","article-title":"European Academy of Neurology guideline on trigeminal neuralgia","volume":"26","author":"Bendtsen","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2023.107208_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-510X(02)00313-1","article-title":"Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study","volume":"205","author":"Blersch","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.toxicon.2023.107208_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/ejp.2120","article-title":"Personalized treatment of neuropathic pain: where are we now?","author":"Bouhassira","year":"2023","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.toxicon.2023.107208_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pain.2003.12.024","article-title":"Development and validation of the neuropathic pain symptom inventory","volume":"108","author":"Bouhassira","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.toxicon.2023.107208_bib11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/j.pain.0000000000002130","article-title":"Stratification of patients based on the Neuropathic Pain Symptom Inventory: development and validation of a new algorithm","volume":"162","author":"Bouhassira","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.toxicon.2023.107208_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12640-012-9314-y","article-title":"Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review","volume":"22","author":"Colosimo","year":"2012","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.toxicon.2023.107208_bib13","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.pain.2014.08.014","article-title":"The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study","volume":"155","author":"Demant","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.toxicon.2023.107208_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","article-title":"Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy","volume":"44","author":"Durham","year":"2004","journal-title":"Headache"},{"key":"10.1016\/j.toxicon.2023.107208_bib15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/ejp.995","article-title":"Bilateral analgesic effects of abobotulinumtoxinA (Dysport\u00ae) following unilateral administration in the rat","volume":"21","author":"Favre-Guilmard","year":"2017","journal-title":"Eur. J. Pain Lond. Engl."},{"key":"10.1016\/j.toxicon.2023.107208_bib16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.toxicon.2023.107208_bib17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1097\/j.pain.0000000000000492","article-title":"Neuropathic pain: an updated grading system for research and clinical practice","volume":"157","author":"Finnerup","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.toxicon.2023.107208_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pain.2008.10.005","article-title":"Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin","volume":"141","author":"Gazerani","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.toxicon.2023.107208_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.pain.2006.04.014","article-title":"The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization","volume":"122","author":"Gazerani","year":"2006","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.toxicon.2023.107208_bib20","first-page":"106","article-title":"The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy","volume":"19","author":"Ghasemi","year":"2014","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.toxicon.2023.107208_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ana.24605","article-title":"Botulinum toxin type A for neuropathic pain in patients with spinal cord injury","volume":"79","author":"Han","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.toxicon.2023.107208_bib22","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/ejp.1941","article-title":"Efficacy and safety of botulinum A toxin for the treatment of chronic peripheral neuropathic pain: a systematic review of randomized controlled trials and meta-analysis","volume":"26","author":"Hary","year":"2022","journal-title":"Eur. J. Pain Lond. Engl."},{"key":"10.1016\/j.toxicon.2023.107208_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0021-5155(99)00197-5","article-title":"Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles","volume":"44","author":"Ishikawa","year":"2000","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.toxicon.2023.107208_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/WNL.40.2.277","article-title":"Botulinum toxin injections for cervical dystonia","volume":"40","author":"Jankovic","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2023.107208_bib25","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.neuroscience.2009.01.066","article-title":"Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction","volume":"159","author":"Kitamura","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.toxicon.2023.107208_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00415-003-0971-x","article-title":"Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin","volume":"250","author":"Kr\u00e4mer","year":"2003","journal-title":"J. Neurol."},{"key":"10.1016\/j.toxicon.2023.107208_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2006.12.004","article-title":"Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain","volume":"145","author":"Luvisetto","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.toxicon.2023.107208_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047977","article-title":"The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves schwann cells and astrocytes","volume":"7","author":"Marinelli","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.toxicon.2023.107208_bib29","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.2147\/JPR.S168650","article-title":"Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis","volume":"11","author":"Meng","year":"2018","journal-title":"J. Pain Res."},{"key":"10.1016\/j.toxicon.2023.107208_bib30","doi-asserted-by":"crossref","first-page":"R297","DOI":"10.1007\/BF02346386","article-title":"Upregulation of calcitonin gene-related peptide at mouse motor nerve terminals poisoned with botulinum type-A toxin","volume":"431","author":"Meunier","year":"1996","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.toxicon.2023.107208_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neurol.2020.01.361","article-title":"Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations","volume":"176","author":"Moisset","year":"2020","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.toxicon.2023.107208_bib32","doi-asserted-by":"crossref","first-page":"25665","DOI":"10.1074\/jbc.M311515200","article-title":"Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity","volume":"279","author":"Morenilla-Palao","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxicon.2023.107208_bib33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s10194-016-0651-8","article-title":"Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Morra","year":"2016","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.toxicon.2023.107208_bib35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.24122","article-title":"Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction","volume":"75","author":"Paterson","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.toxicon.2023.107208_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.21427","article-title":"Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain","volume":"64","author":"Ranoux","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.toxicon.2023.107208_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2007.03.023","article-title":"Botulinum toxin A does not alter capsaicin-induced pain perception in human skin","volume":"260","author":"Schulte-Mattler","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.toxicon.2023.107208_bib38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1213\/01.ane.0000194447.46763.73","article-title":"A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model","volume":"102","author":"Sycha","year":"2006","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.toxicon.2023.107208_bib39","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.dsx.2020.09.019","article-title":"The Effect of Intradermal Botulinum Toxin a injections on painful diabetic polyneuropathy","volume":"14","author":"Taheri","year":"2020","journal-title":"Diabetes Metabol. Syndr."},{"key":"10.1016\/j.toxicon.2023.107208_bib40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pain.2006.10.030","article-title":"Botulinum Toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin","volume":"130","author":"Tugnoli","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.toxicon.2023.107208_bib41","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1212\/01.WNL.0000086374.92906.6A","article-title":"A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A","volume":"61","author":"Voller","year":"2003","journal-title":"Neurology"},{"issue":"Suppl. 4","key":"10.1016\/j.toxicon.2023.107208_bib42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1468-1331.2006.01650.x","article-title":"Clinical value of botulinum toxin in neurological indications","volume":"13","author":"Ward","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2023.107208_bib43","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3390\/toxins13100704","article-title":"Peripherally administered botulinum toxin type A localizes bilaterally in trigeminal ganglia of animal model","volume":"13","author":"Waskitho","year":"2021","journal-title":"Toxins"},{"key":"10.1016\/j.toxicon.2023.107208_bib44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0333102412441721","article-title":"Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Wu","year":"2012","journal-title":"Cephalalgia Int. J. Headache"},{"key":"10.1016\/j.toxicon.2023.107208_bib45","first-page":"1827","article-title":"Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia","volume":"11","author":"Xiao","year":"2010","journal-title":"Pain Med. Malden Mass"},{"key":"10.1016\/j.toxicon.2023.107208_bib46","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/01.wnl.0000345968.05959.cf","article-title":"Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial","volume":"72","author":"Yuan","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2023.107208_bib47","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1129-2377-15-65","article-title":"Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Zhang","year":"2014","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.toxicon.2023.107208_bib48","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/WNF.0b013e31829cb60e","article-title":"Acute treatment of trigeminal neuralgia with onabotulinum toxin A","volume":"36","author":"Z\u00fa\u00f1iga","year":"2013","journal-title":"Clin. Neuropharmacol."}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010123001940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010123001940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:23:06Z","timestamp":1758576186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010123001940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":48,"alternative-id":["S0041010123001940"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2023.107208","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Botulinum toxin A and neuropathic pain: An update","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2023.107208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107208"}}